<!DOCTYPE html>
<html lang="en"><head>
<script src="../../site_libs/clipboard/clipboard.min.js"></script>
<script src="../../site_libs/quarto-html/tabby.min.js"></script>
<script src="../../site_libs/quarto-html/popper.min.js"></script>
<script src="../../site_libs/quarto-html/tippy.umd.min.js"></script>
<link href="../../site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="../../site_libs/quarto-html/light-border.css" rel="stylesheet">
<link href="../../site_libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="../../site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="../../site_libs/quarto-contrib/reveal-header-1.0.0/add_header.js" defer="true"></script>
<link href="../../site_libs/quarto-contrib/reveal-header-1.0.0/add_header.css" rel="stylesheet">
<link href="../../site_libs/quarto-contrib/grid-no-htext-1.0.0/grid_no_htext.css" rel="stylesheet"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.3.433">

  <meta name="author" content="Thomas Debray, PhD">
  <title>time4stats - Introductory Statistics in Clinical Research</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="../../site_libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="../../site_libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="../../site_libs/revealjs/dist/theme/quarto.css">
  <link rel="stylesheet" href="../_assets/styles/additional-styles.css">
  <link href="../../site_libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="../../site_libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="../../site_libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="../../site_libs/revealjs/plugin/reveal-chalkboard/font-awesome/css/all.css" rel="stylesheet">
  <link href="../../site_libs/revealjs/plugin/reveal-chalkboard/style.css" rel="stylesheet">
  <link href="../../site_libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    margin-bottom: 0.5rem;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" data-background-image="../_assets/images/smartdata-logo.png" data-background-position="2% 2%" data-background-size="30%" class="quarto-title-block center">
  <h1 class="title">Introductory Statistics in Clinical Research</h1>
  <p class="subtitle">With a special focus on biosimilar research</p>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Thomas Debray, PhD 
</div>
</div>
</div>

</section>
<section>
<section id="introduction" class="title-slide slide level1 center">
<h1>Introduction</h1>

</section>
<section class="slide level2">

<h3 id="what-is-epidemiology">What is epidemiology?</h3>
<p>Study the occurrence of illness and its relationship to determinants</p>
<ul>
<li>Diagnosis</li>
<li>Etiology (causes)</li>
<li>Prognosis</li>
<li>Treatment of disease</li>
</ul>
</section>
<section class="slide level2">

<h3 id="the-role-of-study-design">The role of study design</h3>
<ol type="1">
<li>Theoretical design</li>
<li>Design of data collection</li>
<li>Design of data analysis</li>
</ol>
</section>
<section class="slide level2">

<h3 id="theoretical-design">Theoretical design</h3>
<p>Formulating the research question in terms of</p>
<ul>
<li>Domain: target population</li>
</ul>
<p>e.g., Adults with relapsing–remitting multiple sclerosis</p>
<ul>
<li>Determinants</li>
</ul>
<p>e.g., Treatment with dimethyl fumarate</p>
<ul>
<li>Outcome</li>
</ul>
<p>e.g., Impairement as measured using the Expanded Disability Status Scale</p>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection">Design of Data Collection</h3>
<p>Prospective</p>
<ul>
<li>Data are yet to be collected and recorded for both outcome and determinants when the study is started</li>
</ul>
<p>Retrospective</p>
<ul>
<li>Data were recorded in the past and are collected after the study is initiated</li>
<li>Prone to missing data</li>
<li>Prone to recall bias</li>
</ul>
<p>Combinations of retrospective and prospective data collection can occur.</p>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-1">Design of Data Collection</h3>
<p><strong>Issue #1</strong>: Time between collection of determinant and outcome information</p>
<ol type="a">
<li><p>Cross-sectional design: data on determinant and outcome are measured simultaneously</p>
<ul>
<li>e.g., a study to estimate the prevalence of relapsing-remitting multiple sclerosis at one point in time</li>
<li>e.g., a study to characterize the first symptoms of multiple sclerosis in patients diagnosed with multiple sclerosis</li>
</ul></li>
<li><p>Longitudinal design: outcome variables are measured over time</p>
<ul>
<li>e.g., a randomized clinical trial to investigate the efficacy and safety of dimethyl fumarate as compared with placebo in patients with relapsing–remitting multiple sclerosis (doi: 10.1056/NEJMoa1206328)</li>
</ul></li>
</ol>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-2">Design of Data Collection</h3>
<p><strong>Issue #2</strong>: Selection of study participants</p>
<p>Census</p>
<ul>
<li>All patients with a certain condition are followed for some time to monitor the development of the outcome</li>
<li>e.g., a registry study to investigate treatment persistence and disability follow-up in consecutive patients with relapsing-remitting multiple sclerosis (doi: <span style="color:blue;">10.1136/jnnp-2018-319831</span>)</li>
</ul>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-3">Design of Data Collection</h3>
<p><strong>Issue #2</strong>: Selection of study participants</p>
<p>Simple random sampling</p>
<ul>
<li>Rather than examining the entire population (census), an equally informative subgroup of the population is studied.</li>
<li>Every subject has an equal chance of being selected for the study</li>
<li>Distribution of determinants in the sample will reliably reflect the distributions in the population experience from whom the sample was drawn</li>
<li>e.g., a national survey to investigate health outcomes and lifestyle in people with multiple sclerosis</li>
</ul>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-4">Design of Data Collection</h3>
<p><strong>Issue #2</strong>: Selection of study participants</p>
<p>Simple random sampling</p>
<ul>
<li>Randomly select study participants within certain strata/subgroups of the population</li>
<li>e.g., a case-control study where researchers recruit incident MS cases from a registry and subsequently construct a random sample of “control” individuals who are similar to the cases but do not have MS. The two groups are then compared with respect to historical determinants (e.g., sleep duration and sleep quality)</li>
<li>Another example, randomization will be stratified based on region or disease history (treatment naïve or not), body weight (common for PK study) and other factor main potentially influence the study measurements.</li>
</ul>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-5">Design of Data Collection</h3>
<p><strong>Issue #2</strong>: Selection of study participants</p>
<p>Non-probability sampling</p>
<ul>
<li>Study participants are selected based on the subjective judgement of the researcher, rather than random selection</li>
<li>e.g., Randomized clinical trials that are based on convenience samples from selected hospitals, including only patients with strict characteristics</li>
</ul>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-6">Design of Data Collection</h3>
<p><strong>Issue #3</strong>: Experimental versus non-interventional (observational) research</p>

<img data-src="images/Picture1.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="design-of-data-collection-7">Design of Data Collection</h3>
<p><strong>Issue #3</strong>: Experimental versus non-interventional (observational) research</p>
<ul>
<li>The term ‘trial’ implies an element of experimentation and a prospective approach in the collection of data, whereas a ‘study’ is a systematic assessment of events that unfold without interfering with their course.</li>
<li>A non-interventional trial may be interpreted as “a study where the medicinal product(s) is (are) prescribed independent to inclusion of the patient in the study and as part of a therapeutic strategy, including diagnostic and monitoring procedures, which is not decided in advance by a study protocol but is applied according to the current clinical practice”</li>
</ul>
<p>Source: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP considerations on the definition of non-interventional trials under the current legislative framework [<span style="color:blue;">ref</span>]</p>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-8">Design of Data Collection</h3>
<p>Examples of non-interventional studies</p>
<ul>
<li>A cross-sectional study to characterize the first symptoms of MS</li>
<li>A survey to investigate health outcomes in people with MS</li>
<li>A post-authorization safety study (PASS) to assess to evaluate the safety and benefit-risk profile of natulizumab as prescribed in routine clinical practice</li>
<li>A drug utilization study (DUS) using registry data to investigate patterns of the usage of medicines in routine clinical practice</li>
<li>A registry study to investigate treatment persistence and disability follow-up in consecutive patients with relapsing-remitting multiple sclerosis (doi: <span style="color:blue;">10.1136/jnnp-2018-319831</span>)</li>
</ul>
</section>
<section class="slide level2">

<h3 id="design-of-data-collection-9">Design of Data Collection</h3>
<p>Examples of experimental clinical trials</p>
<ul>
<li>A phase III clinical trial to investigate the efficacy and safety of dimethyl fumarate as compared with placebo in patients with relapsing–remitting multiple sclerosis (doi: <span style="color:blue;">10.1056/NEJMoa1206328</span>)</li>
<li>A single-arm study where all participants are assigned to receive the experimental intervention after which their results are compared to the patient’s history</li>
</ul>
</section>
<section class="slide level2">

<h3 id="common-study-designs">Common study designs</h3>

<img data-src="images/Picture2.png" style="width:100.0%" class="r-stretch"><p>NIS: Non-interventional study; EXP: experimental study</p>
</section></section>
<section>
<section id="experimental-clinical-trials" class="title-slide slide level1 center">
<h1>Experimental clinical Trials</h1>

</section>
<section class="slide level2">

<h3 id="background">Background</h3>
<p>Key characteristics</p>
<ul>
<li>Prospective experiment of medical intervention(s)</li>
<li>Aim is to measure the intervention effect on prognosis</li>
<li>Exposure groups differ only by intervention(s) of interest</li>
<li>Patients are allocated to the intervention, do not choose it</li>
</ul>
</section>
<section class="slide level2">

<h3 id="background-1">Background</h3>
<p>Key design features</p>
<ul>
<li>Inclusion and exclusion criteria</li>
<li>Control group</li>
<li>Randomisation</li>
<li>Blinding</li>
</ul>
</section>
<section class="slide level2">

<h3 id="eligibility-criteria">Eligibility criteria</h3>
<p>Need to specify which participants are recruited</p>
<ul>
<li>Balance the advantages and disadvantages of having a highly selected group against those associated with including a wide variety of subjects</li>
<li>Narrow eligibility criteria tends to increase statistical power as similar subjects are more likely to respond to the treatment in a similar manner, but increases the difficulty of the recruitment.</li>
<li>Wide eligibility criteria tends to increase generalizability of trial results</li>
</ul>
</section>
<section class="slide level2">

<h3 id="control-group">Control group</h3>
<p>To what reference should the experimental treatment be compared (if any)?</p>
<ul>
<li>Placebo control</li>
<li>Active control</li>
<li>Uncontrolled</li>
<li>Historical control</li>
</ul>
<p>Drugs with no efficacy can seem impressive in uncontrolled trials (e.g.&nbsp;due to placebo effect)</p>
</section>
<section class="slide level2">

<h3 id="randomization">Randomization</h3>
<p>Randomization evenly distributes measured and unmeasured factors&nbsp;among intervention groups</p>
<ul>
<li>Each subject has the same chance of being allocated to any treatment group</li>
<li>The only systematic difference between the study arms should be the treatment given</li>
<li>Any differences in results observed at the end of the trial should be due to the effect of the new treatment, and not to any other factors</li>
<li>Avoids bias and confounding</li>
</ul>
<p>=&gt; Randomization facilitates identification of causal relationships</p>
</section>
<section class="slide level2">

<h3 id="blinding">Blinding</h3>
<p>Aim: to conceal the trial intervention given to each subject</p>
<p>Subjects or researchers may have expectations associated with a particular treatment. This may affect the data integrity:</p>
<ul>
<li>How patients respond to treatment, regarding both efficacy and safety profile.</li>
<li>How the researcher manages or assesses the subject</li>
</ul>
<p>It is generally recommended to blind the subject and anyone involved in giving the treatment, or managing or assessing the subject (double-blinded)</p>
</section>
<section class="slide level2">

<h3 id="trial-design">Trial design</h3>
<p>Parallel group design</p>
<ul>
<li>Patients are each randomised to ONE of the treatment arms</li>
<li>The results from the 2 (or more) groups are compared at the end of the trial</li>
<li>Used when treatments have long-lasting effects</li>
<li>Recommended approach for phase III trials</li>
</ul>

<img data-src="images/Picture3.png" style="width:100.0%" class="r-stretch quarto-figure-center"></section>
<section class="slide level2">

<h3 id="trial-design-1">Trial design</h3>
<p>Crossover design</p>
<ul>
<li>Instead of randomly allocating subjects to treatment arms, the ordering of treatments is random</li>
<li>Washout between treatment periods</li>
<li>Each subject is their own control (eliminates between-subject variability)</li>
<li>Fewer patients needed</li>
<li>Not suitable to investigate long-term outcomes (e.g., safety)</li>
<li>Often used in phase I trials that include a control group</li>
</ul>
</section>
<section class="slide level2">

<h3 id="trial-design-2">Trial design</h3>

<img data-src="images/Picture4.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="phases">Phases</h3>
<p>Four main types of clinical trials</p>

<img data-src="images/Picture5.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="phase-1-trials" class="title-slide slide level1 center">
<h1>Phase 1 trials</h1>

<img data-src="images/Picture6.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="phase-i-trial">Phase I trial</h3>
<p>Typical objectives</p>
<ul>
<li><p>Exploratory</p></li>
<li><p>To determine the pharmacologic and metabolic effects in healthy volunteers</p>
<ul>
<li>Pharmacodynamics (<strong>PD</strong>): physical or biological measures that show the effect of the new drug on the body</li>
<li>Pharmacokinetics (<strong>PK</strong>): physical or biological measures that show how the body deals with the new drug.</li>
</ul></li>
<li><p>To detect the most common side effects</p></li>
</ul>
</section>
<section class="slide level2">

<h3 id="phase-i-trial-1">Phase I trial</h3>
<p>Key endpoints: PK parameters</p>
<ul>
<li>Area under the curve (AUC): quantify total drug exposure</li>
<li><span class="math inline">\(C_{max}\)</span> : The highest concentration level</li>
<li><span class="math inline">\(T_{max}\)</span> : The time at which <span class="math inline">\(C_{max}\)</span> occurs</li>
<li><span class="math inline">\(t_{1/2}\)</span> : terminal half-life, the time it takes for the plasma concentration to decrease by 50% in the final part of the curve, when the drug is being eliminated</li>
</ul>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-i-trial-nct01884935">Example of a phase I trial (NCT01884935)</h3>
<ul>
<li><p>Population</p>
<ul>
<li>Pediatric patients with secondary progressive MS</li>
</ul></li>
<li><p>Interventions</p>
<ul>
<li>Natalizumab 300 mg every 4 weeks for 16 weeks (𝑁=13)</li>
</ul></li>
<li><p>Outcomes:</p>
<ul>
<li>Maximum plasma concentration (<span class="math inline">\(C_{max}\)</span>) of natalizumab</li>
<li>Minimum observed concentration (<span class="math inline">\(C_{min}\)</span>) of natalizumab</li>
<li>Time to maximum observed concentration (<span class="math inline">\(T_{max}\)</span>) of natalizumab</li>
<li>Area under the concentration-time curve from time zero to infinity (<span class="math inline">\(AUC_{inf}\)</span>) of natalizumab</li>
<li>…</li>
</ul></li>
</ul>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-i-trial-nct01884935-1">Example of a phase I trial (NCT01884935)</h3>

<img data-src="images/Picture7.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-i-trial-nct01884935-2">Example of a phase I trial (NCT01884935)</h3>

<img data-src="images/Picture8.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="phase-2-trials" class="title-slide slide level1 center">
<h1>Phase 2 trials</h1>

<img data-src="images/Picture9.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="phase-ii-trial">Phase II trial</h3>
<p>Key characteristics</p>
<ul>
<li>Aim is to obtain a preliminary estimate of efficacy, and/or to determine the optimal dose</li>
<li>Emphasis on safety and intermediate outcomes</li>
<li>Randomization is possible but not essential</li>
</ul>
<p>Example</p>
<ul>
<li>A randomized, blinded, parallel-group, phase 2 study exploring the safety, tolerability, and efficacy of multiple regimens of Natalizumab in adult subjects with relapsing MS.</li>
</ul>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-ii-trial-nct01405820">Example of a phase II trial (NCT01405820)</h3>
<ul>
<li><p>Population</p>
<ul>
<li>Patients with relapsing-remitting MS</li>
</ul></li>
<li><p>Interventions</p>
<ul>
<li>Natalizumab 300 mg intravenous (IV) every 4 weeks for 60 weeks (<span style="color:red;">𝑁=54</span>)</li>
<li>Natalizumab 300 mg subcutaneous (SC)every 4 weeks for 60 weeks (<span style="color:red;">𝑁=45</span>)</li>
<li>Natalizumab 300 mg IV every 12 weeks for 60 weeks (<span style="color:red;">𝑁=52</span>)</li>
<li>Natalizumab 300 mg SC every 12 weeks for 60 weeks (<span style="color:red;">𝑁=54</span>)</li>
<li>Natalizumab 150 mg IV every 12 weeks for 60 weeks (<span style="color:red;">𝑁=47</span>)</li>
<li>Natalizumab 150 mg SC every 12 weeks for 60 weeks (<span style="color:red;">𝑁=38</span>)</li>
</ul></li>
<li><p>Outcomes</p>
<ul>
<li>Cumulative number of combined unique active lesions</li>
</ul></li>
</ul>
</section></section>
<section>
<section id="phase-3-trials" class="title-slide slide level1 center">
<h1>Phase 3 trials</h1>

<img data-src="images/Picture10.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="phase-iii-trial">Phase III trial</h3>
<p>Key characteristics</p>
<ul>
<li>Aim is to obtain a definitive estimate of efficacy</li>
<li>Investigation of <em>clinically relevant</em> outcomes</li>
<li>Randomization is required</li>
<li>Commonly implemented to obtain a marketing licence (“pivotal trial”)</li>
</ul>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-iii-trial-nct00027300">Example of a phase III trial (NCT00027300)</h3>
<p>A 2:1 randomized placebo-controlled trial to determine the safety and efficacy of natalizumab in the treatment of individuals with relapsing multiple sclerosis.</p>
<ul>
<li><p>Population</p>
<ul>
<li>Patients with relapsing-remitting MS</li>
</ul></li>
<li><p>Intervention(s)</p>
<ul>
<li>Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks (<span style="color:red;">𝑁=627</span>)</li>
</ul></li>
<li><p>Comparator(s)</p>
<ul>
<li>Placebo, IV infusion, every 4 weeks, for up to 116 weeks (<span style="color:red;">𝑁=315</span>)</li>
</ul></li>
<li><p>Outcomes</p>
<ul>
<li>Cumulative probability of sustained progression of disability at 2 years</li>
<li>Annualized rate of relapse</li>
</ul></li>
</ul>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-iii-trial-nct00027300-1">Example of a phase III trial (NCT00027300)</h3>
<p>Eligibility criteria</p>
<blockquote>
<p>“Enrollment was limited to men and women who were between the ages of 18 and 50 years and had a diagnosis of relapsing multiple sclerosis; who had a score of 0 to 5.0 on the Expanded Disability Status Scale (EDSS), a rating that ranges from 0 to 10, with higher scores indicating more severe disease; who had undergone magnetic resonance imaging (MRI) showing lesions consistent with multiple sclerosis; and who had had at least one medically documented relapse within the 12 months before the study began. Patients with disease that was categorized as primary progressive, secondary progressive, or progressive relapsing were excluded. Additional exclusion criteria included the following: a relapse within 50 days before the administration of the first dose of the study drug, treatment with cyclophosphamide or mitoxantrone within the previous year, or treatment with interferon beta, glatiramer acetate, cyclosporine, azathioprine, methotrexate, or intravenous immune globulin within the previous 6 months. Patients who had received treatment with interferon beta, glatiramer acetate, or both for more than six months were also excluded.”</p>
</blockquote>
<p><strong>Ref</strong>: Polman CH, et al.&nbsp;A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Engl J Med. 2006 Mar 2;354(9):899–910.</p>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-iii-trial-nct00027300-2">Example of a phase III trial (NCT00027300)</h3>

<img data-src="images/Picture11.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-iii-trial-nct00027300-3">Example of a phase III trial (NCT00027300)</h3>

<img data-src="images/Picture12.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="phase-4-trials" class="title-slide slide level1 center">
<h1>Phase 4 trials</h1>

<img data-src="images/Picture13.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="phase-iv-trial">Phase IV trial</h3>
<p>Key characteristics</p>
<ul>
<li>Aim is to study rare side effects or subgroup of patients and “real-world” effectiveness once the new treatment has been adopted into routine clinical practice</li>
<li>Also known as post-marketing or surveillance studies</li>
<li>Commonly involves investigation of patient-reported outcomes</li>
</ul>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-iv-trial-nct00871780">Example of a phase IV trial (NCT00871780)</h3>
<p>A prospective, open-label, non-randomized clinical trial to determine if natalizumab improves ambulatory measures in relapsing-remitting MS patients.</p>
<ul>
<li><p>Population</p>
<ul>
<li>Patients with relapsing-remitting MS</li>
</ul></li>
<li><p>Intervention(s)</p>
<ul>
<li>Natalizumab 300 mg IV every 4 weeks for 48 weeks (<span style="color:red;">𝑁= 224</span>)</li>
</ul></li>
<li><p>Outcomes</p>
<ul>
<li>Change From Baseline in the Timed 100-meter Walk Test</li>
<li>Change From Baseline in the Timed 25-foot Walk Test</li>
<li>Change From Baseline in Maximum Walking Distance</li>
<li>Change From Baseline in Expanded Disability Status Scale</li>
</ul></li>
</ul>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-iv-trial-nct00871780-1">Example of a phase IV trial (NCT00871780)</h3>

<img data-src="images/Picture14.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="summary">Summary</h3>

<img data-src="images/Picture15.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="analysis-of-clinical-trials" class="title-slide slide level1 center">
<h1>Analysis of clinical trials</h1>

</section>
<section class="slide level2">

<p>Experimental clinical Trials</p>
<h3 id="estimation-of-treatment-effect">Estimation of treatment effect</h3>
<p>In randomized clinical trials, we can quantify the treatment effect of drug A (active) versus drug B (control) as follows:</p>

<img data-src="images/Picture16.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="estimation-of-treatment-effect-1">Estimation of treatment effect</h3>

<img data-src="images/Picture17.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="estimation-of-treatment-effect-2">Estimation of treatment effect</h3>
<p>If the data are assumed to be normally distributed, an approximate 95% confidence interval is given by <span style="color:blue;">Mean ± (SD/sqrt(n)*1.96)</span></p>

<img data-src="images/Picture18.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="formal-testing-of-treatment-effects">Formal testing of treatment effects</h3>
<p>Hypothesis test to evaluate the difference between two (or more) drugs</p>
<ul>
<li><span class="math inline">\(𝐻_0\)</span> : Null hypothesis</li>
<li><span class="math inline">\(𝐻_1\)</span> : Alternative hypothesis</li>
<li>Aim is to reject <span class="math inline">\(𝐻_0\)</span></li>
</ul>
<p>We assume that <span class="math inline">\(𝐻_0\)</span> is true and subsequently determine the likelihood of the observed data. This results in a p-value (= the probability that an effect as large as that observed, or more if <span class="math inline">\(𝐻_0\)</span> is true)</p>
</section>
<section class="slide level2">

<h3 id="formal-testing-of-treatment-effects-1">Formal testing of treatment effects</h3>
<p>Interpretation of p-values</p>
<ul>
<li>P-values &lt; 0.05 provide evidence to reject <span class="math inline">\(𝐻_0\)</span> (and usually indicate that drug A is superior / non-inferior / equivalent to drug B)</li>
<li>P-values &gt; 0.05 indicate that there is not enough evidence to reject <span class="math inline">\(𝐻_0\)</span> (which does not necessarily mean that <span class="math inline">\(𝐻_0\)</span> is true)</li>
</ul>

<img data-src="images/Picture19.png" style="width:100.0%" class="r-stretch quarto-figure-center"></section>
<section class="slide level2">

<h3 id="formal-testing-of-treatment-effects-2">Formal testing of treatment effects</h3>
<p>Possible reasons for p&gt;0.05</p>
<ul>
<li>There really is no difference</li>
<li>There is a real difference, but by chance the sample of subjects did not show this</li>
<li>There is a real difference, but the trial had too few subjects, and therefore insufficient power, to detect it.</li>
</ul>
<p>Absence of evidence ≠ evidence of absence</p>
</section>
<section class="slide level2">

<h3 id="formal-testing-of-treatment-effects-3">Formal testing of treatment effects</h3>

<img data-src="images/Picture20.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="formal-testing-of-treatment-effects-4">Formal testing of treatment effects</h3>

<img data-src="images/Picture21.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="formal-testing-of-treatment-effects-5">Formal testing of treatment effects</h3>

<img data-src="images/Picture22.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="formal-testing-of-treatment-effects-6">Formal testing of treatment effects</h3>
<p>Determination of a clinically meaningful difference <span class="math inline">\(\delta\)</span></p>
<ul>
<li><p>Different choice of 𝛿 may affect the sample size calculation</p></li>
<li><p>The margin <span class="math inline">\(\delta\)</span> should be based on both statistical reasoning and clinical judgment</p>
<ul>
<li>Previous placebo-controlled trials similar to those planned for the new trial (ICH 10 guideline)</li>
<li>Systematic literature review</li>
<li>Limits proposed by FDA and/or EMA (e.g., bioequivalence trials)</li>
</ul></li>
<li><p>One of the most controversial subjects in drug development</p></li>
</ul>
</section>
<section class="slide level2">

<h3 id="errors-when-testing-hypotheses">Errors when testing hypotheses</h3>
<ul>
<li>There is a chance that we incorrectly fail to reject <span class="math inline">\(𝐻_0\)</span></li>
<li>There is a chance that we incorrectly reject <span class="math inline">\(𝐻_0\)</span></li>
<li>The chance of error needs to be controlled</li>
</ul>

<img data-src="images/Picture23.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="type-i-error">Type I error</h3>

<img data-src="images/Picture24.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="type-ii-error">Type II error</h3>

<img data-src="images/Picture25.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="controlling-type-i-and-type-ii-errors">Controlling type I and type II errors</h3>

<img data-src="images/Picture26.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="confidence-intervals">Confidence intervals</h3>

<img data-src="images/Picture27.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="sample-size-estimation">Sample size estimation</h3>

<img data-src="images/Picture28.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="sample-size-estimation-1">Sample size estimation</h3>

<img data-src="images/Picture29.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="clinical-trials-for-biosimilars" class="title-slide slide level1 center">
<h1>Clinical trials for biosimilars</h1>

</section>
<section class="slide level2">

<h3 id="introduction-1">Introduction</h3>
<p>A biosimilar medicine is a biological medicine that is developed to be highly similar and clinically equivalent to an existing medicine.</p>
<ul>
<li>A biosimilar contains a version of an active substance of an already approved biological medicine, which is referred to as the ‘<span style="color:red;">reference medicine</span>’.</li>
<li>Similarity to the reference medicine must be established based on a comprehensive biosimilar comparability exercise, such that they do not have any clinically meaningful differences from the reference medicine in terms of quality, biological activity, safety, efficacy and immunogenicity.</li>
</ul>
</section>
<section class="slide level2">

<h3 id="introduction-2">Introduction</h3>
<p>A biosimilar is not regarded as a generic of a biological medicine.</p>
<ul>
<li>This is mostly because the natural variability and more complex manufacturing of biological medicines do not allow an exact replication of the molecular microheterogeneity.</li>
<li>Consequently, more studies are needed for regulatory approval of biosimilars than for generics to ensure that minor differences do not affect safety or efficacy.</li>
</ul>
</section>
<section class="slide level2">

<h3 id="introduction-3">Introduction</h3>

<img data-src="images/Picture30.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="clinical-development-plan-cdp">Clinical Development Plan (CDP)</h3>

<img data-src="images/Picture1.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="phase-1-biosimilar-trials" class="title-slide slide level1 center">
<h1>Phase 1 biosimilar trials</h1>

<img data-src="images/Picture32.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="clinical-development-plan">Clinical Development Plan</h3>
<p><strong>Phase I</strong></p>
<ul>
<li>Randomized to 2-3 arms including the reference product(s)</li>
<li>Need to <span style="color:green;">prove</span> the bio-equivalence of PK parameters</li>
<li>Requires larger sample size than phase I trials of innovative drugs</li>
<li>Blinded sample size re-assessment is often needed</li>
<li>Recommend parallel design other than cross-over design from FDA.</li>
</ul>
</section>
<section class="slide level2">

<h3 id="examples">Examples</h3>

<img data-src="images/Picture33.png" style="width:100.0%" class="r-stretch"><p>HV = Healthy volunteers</p>
<ul>
<li>The reference product was studied in 2 separate arms: one US-sourced drug and one EU-sourced drug</li>
</ul>
</section>
<section class="slide level2">

<h3 id="pharmacokinetic-parameters">Pharmacokinetic parameters</h3>
<p>The trial should demonstrate bio-equivalence for various PK parameters</p>
<ul>
<li>Area under the blood or plasma concentration–time curve (AUC)</li>
<li>Maximum concentration Cmax</li>
</ul>
<p><strong>Ref</strong>: Committee for medicinal products for human use (CHMP). Guideline on the investigation of bioequivalence. London, UK: European Medicines Agency; 2010 Jan.&nbsp;Report No.: CPMP/EWP/QWP/1401/98.</p>
</section>
<section class="slide level2">

<h3 id="requirements-for-hypothesis-testing">Requirements for hypothesis testing</h3>
<ul>
<li>Hypothesis testing should be based on the ratio of the population geometric means</li>
<li>The 90% confidence interval for the ratio of the test and reference products should be contained within the acceptance interval of 80.00 to 125.00%.</li>
<li>A margin of clinical equivalence (∆) is chosen by defining the largest difference that is clinically acceptable, so that a difference bigger than this would matter in practice.</li>
<li>The data should be transformed prior to analysis using a logarithmic transformation and subsequently be analyzed using ANOVA</li>
</ul>
<p><strong>Ref</strong>: Committee for medicinal products for human use (CHMP). Guideline on the investigation of bioequivalence. London, UK: European Medicines Agency; 2010 Jan.&nbsp;Report No.: CPMP/EWP/QWP/1401/98.</p>
</section>
<section class="slide level2">

<h3 id="hypothesis-test-for-pk-parameters">Hypothesis test for PK parameters</h3>
<p>Consider a PK parameter that follows a log-normal distribution (e.g., <span class="math inline">\(C_{max}\)</span> or AUC)</p>
<p>We can assess equivalence by testing the following hypothesis:</p>
<ul>
<li><p><strong>Null hypothesis</strong>: the drugs are not equivalent</p>
<p><span class="math inline">\(𝐻_0\)</span>: <span class="math inline">\(\mu_{biosimilar}\)</span>/<span class="math inline">\(\mu_{reference}\)</span> ≤ 80% or <span class="math inline">\(\mu_{biosimilar}\)</span>/<span class="math inline">\(\mu_{reference}\)</span> ≥125%</p></li>
<li><p>Alternative hypothesis: the drugs are equivalent</p>
<p><span class="math inline">\(𝐻_1\)</span>: 80% &lt; <span class="math inline">\(\mu_{biosimilar}\)</span>/<span class="math inline">\(\mu_{reference}\)</span> &lt;125%</p></li>
<li><p>The equivalence margins 80% and 125% are set by regulators.</p></li>
</ul>
<p>Note: We use the geometric mean for 𝜇 because data are skewed (the geometric mean can be approximated using the median)</p>
</section>
<section class="slide level2">

<h3 id="hypothesis-test-for-pk-parameters-1">Hypothesis test for PK parameters</h3>

<img data-src="images/Picture34.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="testing-of-multiple-endpoints">Testing of multiple endpoints</h3>
<p>It is often required to investigate equivalence for more than one primary variable. For example, EMA recommends showing equivalence both for AUC and Cmax</p>
<p>A decision must be made as to whether it is desirable to</p>
<ul>
<li><p>Demonstrate equivalence for <span style="color:red;">all</span> primary endpoints : <strong>most common setting</strong></p>
<p>(also known as “multiple co-primary endpoints”)</p></li>
<li><p>Demonstrate equivalence for <span style="color:red;">at least one</span> of the primary endpoints</p>
<p>(also known as “multiple primary endpoints”)</p></li>
</ul>
<p><strong>Ref</strong>: Sozu T, Sugimoto T, Hamasaki T, Evans SR. Sample Size Determination in Clinical Trials with Multiple Endpoints. Cham: Springer International Publishing; 2015.</p>
</section>
<section class="slide level2">

<h3 id="testing-of-multiple-co-primary-endpoints">Testing of multiple co-primary endpoints</h3>
<p>When the trial aims to evaluate the joint effects on <strong>all</strong> of the <span class="math inline">\(m\)</span> <span style="color:red;">co-primary</span> endpoints</p>
<ul>
<li><p>Equivalence has to be shown for all 𝑚 tests</p></li>
<li><p>No multiplicity adjustment is needed to control the type I error rate because all hypotheses have to be rejected</p></li>
<li><p>The <span style="color:red;">type II error rate increases</span> as the number of endpoints to be evaluated increases</p>
<ul>
<li>The power to reject non-equivalence decreases (for a fixed sample size)</li>
<li>The probability that the trial will be “successful” decreases (for a fixed sample size)</li>
</ul></li>
</ul>
<p><strong>Ref</strong>: Sozu T, Sugimoto T, Hamasaki T, Evans SR. Sample Size Determination in Clinical Trials with Multiple Endpoints. Cham: Springer International Publishing; 2015.</p>
</section>
<section class="slide level2">

<h3 id="testing-of-multiple-co-primary-endpoints-1">Testing of multiple co-primary endpoints</h3>

<img data-src="images/Picture35.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="testing-of-multiple-co-primary-endpoints-2">Testing of multiple co-primary endpoints</h3>
<p>Increase in sample size can be extreme, especially if</p>
<ul>
<li>No correlation exists between the test statistics</li>
<li>Many tests are carried out</li>
</ul>
<p>One possible solution, if the required sample size is not feasible, is to power the study so that at least k out of m tests have to meet the equivalence criterion</p>
</section>
<section class="slide level2">

<h3 id="testing-of-multiple-primary-endpoints">Testing of multiple primary endpoints</h3>

<img data-src="images/Picture36.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="testing-of-multiple-primary-endpoints-1">Testing of multiple primary endpoints</h3>

<img data-src="images/Picture37.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="testing-of-multiple-primary-endpoints-2">Testing of multiple primary endpoints</h3>

<img data-src="images/Picture38.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="testing-of-multiple-primary-endpoints-3">Testing of multiple primary endpoints</h3>

<img data-src="images/Picture39.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="testing-of-multiple-primary-endpoints-4">Testing of multiple primary endpoints</h3>

<img data-src="images/Picture40.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="adaptive-trial-designs">Adaptive trial designs</h3>
<ul>
<li>Trial specifications are often based on preliminary and/or uncertain information</li>
<li>Performing a study in a fixed sample size design implies a considerable risk of resulting in a too high or too low sample size.</li>
<li>It is desirable to terminate the trial when the treatment seems to be ineffective.</li>
</ul>
</section>
<section class="slide level2">

<h3 id="adaptive-trial-designs-1">Adaptive trial designs</h3>
<p>We can adopt a multi-stage design to</p>
<ul>
<li>Recruit a portion of the planned sample</li>
<li>Recalculate the sample size based on the observed variability (without unblinding treatment allocation)</li>
<li>Determine whether a test drug is promising enough to warrant further testing</li>
</ul>
</section>
<section class="slide level2">

<h3 id="adaptive-trial-designs-2">Adaptive trial designs</h3>
<p>Sample size re-estimation in bioequivalence studies inflates the type I error according to</p>
<ul>
<li>The required sample size</li>
<li>The sample size of the internal pilot study</li>
<li>The standardized equivalence or non-inferiority margin</li>
</ul>
<p>The elevation of the significance level is negligible for most practical situations.</p>
<p><strong>Ref</strong>: Friede T, Kieser M. Blinded sample size reassessment in non-inferiority and equivalence trials. Statist Med. 2003 Mar 30;22(6):995–1007.</p>
</section>
<section class="slide level2">

<h3 id="simulations-for-sample-size-estimation">Simulations for sample size estimation</h3>
<p>Empirical sample size estimation through simulation</p>
<ul>
<li>Testing for equivalence on (co-)primary endpoints</li>
<li>Evaluate the decrease in power due to multiple testing</li>
<li>Evaluate impact of adaptive design choices</li>
<li>Empirically assess type I and type II error as a function of sample size and other parameters</li>
</ul>
<p><strong>Ref</strong>: Mielke J, Jones B, Jilma B, König F. Sample Size for Multiple Hypothesis Testing in Biosimilar Development. Statistics in Biopharmaceutical Research. 2018 Jan 2;10(1):39–49.</p>
</section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture41.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-1">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture42.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-2">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture43.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-3">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture44.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-4">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture45.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-5">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture46.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-6">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture47.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-7">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture48.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-8">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture49.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-9">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture50.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-10">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture51.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-11">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture52.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-12">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture53.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="example-of-a-phase-1-biosimilar-study-nct01922336-13">Example of a phase 1 biosimilar study (NCT01922336)</h3>

<img data-src="images/Picture54.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="phase-3-biosimilar-trials" class="title-slide slide level1 center">
<h1>Phase 3 biosimilar trials</h1>

<img data-src="images/Picture55.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="clinical-development-plan-of-phase-3">Clinical Development Plan of Phase 3</h3>

<img data-src="images/Picture56.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="clinical-development-plan-of-phase-3-1">Clinical Development Plan of Phase 3</h3>
<p>Key differences in sample size estimation</p>
<ul>
<li>Choice of endpoint (preferences may differ between EMA and FDA)</li>
<li>Data distribution: Normal, Binary, Binomial, etc.</li>
<li>Choice and justification of equivalence margin (e.g., clinical relevance)</li>
</ul>
<p>Equivalence should be demonstrated for all (primary) endpoints for all comparisons between the bio-similar and the (EU-sourced and US-sourced) reference drug</p>
</section>
<section class="slide level2">

<h3 id="clinical-development-plan-of-phase-3-2">Clinical Development Plan of Phase 3</h3>

<img data-src="images/Picture57.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="clinical-development-plan-of-phase-3-3">Clinical Development Plan of Phase 3</h3>

<img data-src="images/Picture58.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="clinical-development-plan-of-phase-3-4">Clinical Development Plan of Phase 3</h3>

<img data-src="images/Picture59.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="software-for-sample-size-estimation" class="title-slide slide level1 center">
<h1>Software for sample size estimation</h1>

</section>
<section class="slide level2">

<h3 id="integral-simulation-for-2-treatment-arms-1-outcome">Integral Simulation for 2 Treatment Arms &amp; 1 Outcome</h3>
</section></section>
<section>
<section id="a-shiny-app" class="title-slide slide level1 center">
<h1>A Shiny App</h1>

</section>
<section class="slide level2">

<h3 id="apps-structure">App’s Structure</h3>
<ol type="1">
<li><p>LANDING PAGE</p>
<ul>
<li>A pop-up display to choose sample calculation method.</li>
</ul></li>
<li><p>INPUT PANEL</p>
<ul>
<li>A panel to input parameters needed to calculate the sample. It is changed dynamically depends on the method chosen.</li>
</ul></li>
<li><p>OUTPUT PANEL</p>
<ul>
<li>Displays the result of calculation/simulation with the respective input.</li>
</ul></li>
</ol>
</section>
<section class="slide level2">

<h3 id="landing-page">Landing Page</h3>

<img data-src="images/Picture60.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="input-panel">Input Panel</h3>

<img data-src="images/Picture61.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="input-panel-2">Input Panel (2)</h3>

<img data-src="images/Picture62.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="input-panel-3">Input Panel (3)</h3>

<img data-src="images/Picture63.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="output-panel">Output Panel</h3>

<img data-src="images/Picture64.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="output-panel-1">Output Panel</h3>

<img data-src="images/Picture65.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="generated-report">Generated Report</h3>

<img data-src="images/Picture66.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="generated-report-2">Generated Report (2)</h3>

<img data-src="images/Picture67.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="non-randomized-intervention-studies" class="title-slide slide level1 center">
<h1>Non-randomized Intervention Studies</h1>

</section>
<section class="slide level2">

<h3 id="randomization-1">Randomization</h3>

<img data-src="images/Picture68.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="limitations-of-randomized-trials">Limitations of randomized trials</h3>

<img data-src="images/Picture69.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="limitations-of-randomized-trials-1">Limitations of randomized trials</h3>

<img data-src="images/Picture70.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="the-efficacy-effectiveness-gap">The efficacy-effectiveness gap</h3>

<img data-src="images/Picture71.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="what-is-real-world-data-rwd">What is real-world data (RWD)?</h3>

<img data-src="images/Picture72.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="what-is-real-world-data-rwd-1">What is real-world data (RWD)?</h3>
<p>Routinely collected data relating to a patient’s health status or the delivery of health care from a variety of sources other than traditional clinical trials</p>
<p><strong>Primary research data</strong></p>
<ul>
<li>New data collection</li>
<li>E.g., data collected for an ad hoc study or a prospective patient registry</li>
</ul>
<p><strong>Secondary research data</strong></p>
<ul>
<li>Analysis of existing data</li>
<li>E.g., data from (inter)national databases or electronic healthcare records</li>
</ul>
</section>
<section class="slide level2">

<h3 id="sources-of-real-world-data">Sources of real-world data</h3>

<img data-src="images/Picture73.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="sources-of-real-world-data-1">Sources of real-world data</h3>
<p><strong>Clinical Practice Research Datalink | CPRD</strong></p>
<p>The CPRD database contains coded and anonymised EHR data from &gt;2000 primary care practices in UK capturing information on:</p>
<ul>
<li>Demographic characteristics</li>
<li>Diagnoses and symptoms</li>
<li>Drug exposures</li>
<li>Vaccination history</li>
<li>Laboratory tests</li>
<li>Referrals to hospital and specialist care</li>
</ul>
</section>
<section class="slide level2">

<h3 id="sources-of-real-world-data-2">Sources of real-world data</h3>

<img data-src="images/Picture74.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="sources-of-real-world-data-3">Sources of real-world data</h3>

<img data-src="images/Picture75.png" style="width:100.0%" class="r-stretch"></section></section>
<section>
<section id="real-world-evidence" class="title-slide slide level1 center">
<h1>Real-world Evidence</h1>

</section>
<section class="slide level2">

<h3 id="what-is-real-world-evidence-rwe">What is real-world evidence (RWE)?</h3>
<ul>
<li><p>Information derived from the analysis of RWD</p>
<ul>
<li>Observational studies</li>
<li>Administrative (e.g., claims) databases</li>
<li>Registries</li>
<li>Wearable devices</li>
<li>…</li>
</ul></li>
<li><p>Information derived from combining clinical trial data and RWD</p>
<ul>
<li>Incorporation of historical controls</li>
<li>Indirect treatment comparisons</li>
</ul></li>
</ul>
</section>
<section class="slide level2">

<h3 id="real-world-evidence-studies">Real-world evidence studies</h3>
<p>Well-designed, well-executed, and well reported nonrandomized observational studies are a critical component of the body of evidence</p>
<ul>
<li><p>RWE studies may help to identify how new drugs are utilized and impacted under routine prescribing practice</p></li>
<li><p>Results of RCTs and non-randomised studies do not inevitably differ [ref, ref, ref]</p>
<p>(especially if statistical analyse target the same estimands)</p></li>
<li><p>High degree of reproducibility for RWE studies with good methodological transparency [ref]</p></li>
</ul>
</section>
<section class="slide level2">

<h3 id="use-of-real-world-evidence">Use of real-world evidence</h3>

<img data-src="images/Picture76.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="rwe-from-prospective-cohort-studies">RWE from prospective cohort studies</h3>

<img data-src="images/Picture77.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="rwe-from-registry-based-studies">RWE from registry-based studies</h3>

<img data-src="images/Picture78.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="rwe-from-pragmatic-trials">RWE from pragmatic trials</h3>

<img data-src="images/Picture79.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="leveraging-rwd-in-clinical-trials">Leveraging RWD in clinical trials</h3>
<p>Incorporation of historical data during the design and analysis of clinical trials may help to:</p>
<ul>
<li>Lower both cost and trial duration</li>
<li>Facilitate participant recruitment</li>
<li>Address ethical barriers (e.g.&nbsp;pediatric studies)</li>
</ul>
</section>
<section class="slide level2">

<h3 id="rwe-studies-what-is-the-catch">RWE studies – what is the catch?</h3>
<p>The analysis of real-world data is prone to various sources of bias.</p>
<ul>
<li>The Achilles heel of observational studies is error due to imbalance in unobserved variables</li>
</ul>

<img data-src="images/Picture80.png" style="width:100.0%" class="r-stretch quarto-figure-center"></section>
<section class="slide level2">

<h3 id="rwe-studies-what-is-the-catch-1">RWE studies – what is the catch?</h3>

<img data-src="images/Picture81.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="rwe-studies-what-is-the-catch-2">RWE studies – what is the catch?</h3>
<p>Missing data</p>
<ul>
<li>Key variables and outcomes are not always measured or collected</li>
<li>Lack of data may be informative</li>
<li>Right censoring, e.g., loss to follow-up</li>
<li>Interval censoring, e.g., when observing an AE requires follow-ups or inspections</li>
<li>Left censoring</li>
<li>Lack of time zero data (especially when making secondary use of RWD)</li>
</ul>
</section>
<section class="slide level2">

<h3 id="rwe-studies-what-is-the-catch-3">RWE studies – what is the catch?</h3>
<p>Heterogeneity</p>
<ul>
<li>Routine clinical practice (e.g., treatment options, dosage)</li>
<li>Variable &amp; outcome definitions</li>
<li>Visit schedules and patient follow-up</li>
<li>Quality and completeness of relevant data sources</li>
<li>Analysis methods [ref] (e.g.&nbsp;when combining data across multiple registries)</li>
</ul>
</section>
<section class="slide level2">

<h3 id="rwe-studies-what-is-the-catch-4">RWE studies – what is the catch?</h3>

<img data-src="images/Picture82.png" style="width:100.0%" class="r-stretch"></section>
<section class="slide level2">

<h3 id="appraising-the-quality-of-rwe">Appraising the quality of RWE</h3>
<p><img data-src="images/Picture83.png" style="width:100.0%"></p>

<p><img src="../_assets/images/copyright.svg" class="slide-logo"></p>
<div class="footer footer-default">
<p><a href="https://fromdatatowisdom.com/" class="uri">https://fromdatatowisdom.com/</a></p>
</div>
<div class="reveal-header">
<div class="header-logo" data-hide-from-titleslide="true">
<img data-src="../_assets/images/smartdata-logo.png">
</div>
<div class="sc-title">
<p> </p>
</div>
<div class="header-text" data-hide-from-titleslide="true">
<p> </p>
</div>
<div class="sb-title">
<p> </p>
</div>
</div>
</section></section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="../../site_libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="../../site_libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="../../site_libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="../../site_libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="../../site_libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="../../site_libs/revealjs/plugin/reveal-chalkboard/plugin.js"></script>
  <script src="../../site_libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="../../site_libs/revealjs/plugin/notes/notes.js"></script>
  <script src="../../site_libs/revealjs/plugin/search/search.js"></script>
  <script src="../../site_libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="../../site_libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': false,
'previewLinksAuto': true,
'smaller': true,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleChalkboard(event)\"><kbd>b</kbd> Toggle Chalkboard</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleNotesCanvas(event)\"><kbd>c</kbd> Toggle Notes Canvas</a></li>\n<li class=\"slide-tool-item\" data-item=\"6\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.downloadDrawings(event)\"><kbd>d</kbd> Download Drawings</a></li>\n<li class=\"slide-tool-item\" data-item=\"7\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'chalkboard': {"buttons":false},
'smaller': true,
 
        // Display controls in the bottom right corner
        controls: true,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: false,

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'none',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.2,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, RevealChalkboard, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Copied!");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Copied!");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn) {
        const config = {
          allowHTML: true,
          content: contentFn,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start'
        };
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>